Pharmacogenetics of irinotecan toxicity

Pharmacogenomics

Volumn 5, Issue 7, 2004, Pages 835-843

  Marsh, Sharon ^a   McLeod, Howard L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug pathway; Irinotecan; Pharmacogenetics; Toxicity; UGT1A1

Indexed keywords

BEVACIZUMAB; CARBOXYLESTERASE; CETUXIMAB; CYTOCHROME P450 3A; DIFLOMOTECAN; DNA TOPOISOMERASE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE; IRINOTECAN; OXALIPLATIN; TOPOTECAN;

AREA UNDER THE CURVE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CORRELATION ANALYSIS; CYTOTOXICITY; DIARRHEA; DINUCLEOTIDE REPEAT; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GILBERT DISEASE; HAPLOTYPE; HUMAN; NEUTROPENIA; NONHUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; RACE DIFFERENCE; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; HUMANS; PHARMACOGENETICS;

EID: 6344231838     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.7.835     Document Type: Review

References (59)

1. Wall ME, Wani MC: Camptothecin and taxol: discovery to clinic - thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 55, 753-760 (1995).
2. Rothenberg ML: Topoisomerase I inhibitors: review and update. Ann. Oncol. 8, 837-855 (1997).
3. Abang AM: The clinical pharmacology of topoisomerase I inhibitors. Semin. Hematol. 35, 13-21 (1998).
4. Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF: Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin. Oncol. 23, 11-20 (1996).
5. Lavergne O, Demarquay D, Kasprzyk PG, Bigg DC: Homocamptothecins: E-ring modified CPT analogues. Ann. NY Acad. Sci. 922, 100-111 (2000).
6. Saltz LB, Cox JV, Blanke C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl.J. Med. 343, 905-914 (2000).
7. Hurwitz H, Fehrenbacher L, Novotny W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
8. Hoff PM, Pazdur R: Progress in the development of novel treatments for colorectal cancer. Oncology (Huntingt.) 18, 705-708 (2004).
9. Goldberg RM, Sargent DJ, Morton RF et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22, 23-30 (2004).
10. Fuchs CS, Moore MR, Harker G et al.: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J. Clin. Oncol. 21, 807-814 (2003).
11. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
12. Marsh S, McLeod HL: Cancer pharmacogenetics. Br. J. Cancer. 90, 8-11 (2004).
13. McLeod HL: Drug pathways: moving beyond single gene pharmacogenetics. Pharmacogenomics 5, 139-141 (2004).
14. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat. 6, 71-84 (2003).
15. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 60, 1189-1192 (2000).
16. Santos A, Zanetta S, Cresteil T et al.: Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin. Cancer Res. 6, 2012-2020 (2000).
17. Ciotti M, Basu N, Brangi M, Owens IS: Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem. Biophys. Res. Commun. 260, 199-202 (1999).
18. Park SY, Lam W, Cheng YC: X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res. 62, 459-465 (2002).
19. Chatterjee S, Cheng MF, Trivedi D, Petzold SJ, Berger NA: Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines. Cancer Commun. 1, 389-394 (1989).
20. Miknyoczki SJ, Jones-Bolin S, Pritchard S et al.: Chemopotentiation of temozolomide, irinotecan, and cisplatin activiry by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther. 2, 371-382 (2003).
21. Pouliot JJ, Robertson CA, Nash HA: Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae. Genes Cells 6, 677-687 (2001).
22. Pouliot JJ, Yao KC, Robertson CA, Nash HA: Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. Science 286, 552-555 (1999).
23. Reid RJ, Fiorani P, Sugawara M, Bjornsti MA: CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage. Proc. Natl. Acad. Sci. USA 96, 11440-11445 (1999).
24. Cusack JC, Jr., Liu R, Houston M et al.: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res. 61, 3535-3540 (2001).
25. Valente P, Arzani D, Cesario A et al.: TNF increases camptothecin-induced apoptosis by inhibition of NF-κB. Eur. J. Cancer 39, 1468-1477 (2003).
26. The International HapMap Project. Nature 426, 789-796 (2003).
27. Sai K, Kaniwa N, Itoda M et al.: Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13, 741-757 (2003 ).
28. Kroetz DL, Pauli-Magnus C, Hodges LM et al.: Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13, 481-494 (2003).
29. Saito S, Iida A, Sekine A et al.: Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J. Hum. Genet. 47, 38-50 (2002).
30. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473-3478 (2000).
31. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75, 13-33 (2004).
32. Kim RB, Leake BF, Choo EF et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70, 189-199 (2001).
33. Mathijssen RH, Marsh S, Karlsson MO et al.: Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res. 9, 3246-3253 (2003).
34. Ameyaw MM, Regateiro F, Li T et al.: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11, 217-221 (2001).
35. Kim RB: MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 12, 425-427 (2002).
36. Innocenti F, Undevia SD, Chen PX et al.: Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: evidence for a functional variant of ABCC2. Proc. Am. Assoc. Clin. Oncol. 23, 129 (2004).
37. Schellens JH, Maliepaard M, Scheper RJ et al.: Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann. NY Acad. Sci. 922, 188-194 (2000).
38. Candeil L, Gourdier I, Peyron D et al.: ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int. J. Cancer 109, 848-854 (2004).
39. Imai Y, Nakane M, Kage K et al.: C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 1, 611-616 (2OO2).
40. Hustert E, Zibat A, Presecan-Siedel E et al.: Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. 29, 1454-1459 (2001).
41. Sanghani SP, Quinney SK, Fredenburg TB et al.: Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Clin. Cancer Res. 9, 4983-4991 (2003).
42. Zhang W, Xu G, McLeod HL: Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis. Appl. Immunohistochem. Mol. Morphol. 10, 374-380 (2002).
43. Xu G, Zhang W, Ma MK, McLeod HL: Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin. Cancer Res. 8, 2605-2611 (2002).
44. Marsh S, Xiao M, Yu J et al.: Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics (In press).
45. Wu MH, Chen P, Remo BF et al.: Characterization of multiple promoters in the human carboxylesterase 2 gene. Pharmacogenetics 13, 425-435 (2003).
46. Gong QH, Cho JW, Huang T et al.: Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11, 357-368 (2001).
47. Innocenti F, Ratain MJ: Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Huntingt.) 17, 52-55 (2003).
48. Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl. Acad. Sci. USA 95, 8170-8174 (1998).
49. Guillemette C, Millikan RC, Newman B, Housman DE: Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res. 60, 950-956 (2000).
50. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A: Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 9, 591-599 (1999).
51. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926 (2000).
52. Iyer L, Hall D, Das S et al.: Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 65, 576-582 (1999).
53. Iyer L, Das S, Janisch L et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2, 43-47 (2002).
54. Marcuello E, Altes A, Menoyo A et al.: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91, 678-682 (2004).
55. McLeod H, Sargent D, Marsh S et al.: Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)/CPT- 11, 5FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer. Proc. Am. Assoc. Clin. Oncol. 22, 252 (2003).
56. Rouits E, Boisdron-Celle M, Dumont A et al.: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10, 5151-5159 (2004).
57. Innocenti F, Undevia SD, Iyer L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388 (2004).
58. Innocenti F, Grimsley C, Das S et al.: Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12, 725-733 (2002).
59. Sai K, Saeki M, Saito Y et al.: UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75, 501-515 (2004).